Submission ID 91944
| Poster Code | HR-P-81 |
|---|---|
| Title of Abstract | Taming the Cytokine Storm by Modulating the NF-κβ butterfly effect: Repurposing Montelukast for the attenuation and prophylaxis of COVID-19 symptoms |
| Abstract Submission | The two main complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are the development of acute respiratory distress syndrome (ARDS), as well as the development of complications from a hyperinflammatory cytokine profile (a cytokine storm). NF-κβ (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex involved in cytokine production and inflammation, with attenuation of NF-κβ associated with a reduction in cytokine production. Montelukast, an FDA and Health Canada approved asthma drug, has been shown to inhibit the signalling of NF-κβ, and other proinflammatory mediators, such as interleukin-6,8,10, TNF-α, MCP-1. Herein, we outline the scientific rational behind our hypothesis that repurposing Montelukast to target suppression of NF-κβ activation in COVID-19 positive patients will result in a corresponding reduction of proinflammatory mediators, thereby attenuating cytokine production, and dampening of the cytokine storm. Additionally, we postulate that a reduction in proinflammatory mediators by Montelukast will result in a mitigation of severe COVID-19 symptoms and serve as a therapeutic for SARS-CoV-2 infections. In this manner, we propose to target attenuation of COVID-19 symptoms, rather than the virus, as an effective therapeutic strategy to improve COVID-19 related clinical outcomes. In support of our hypothesis, we explore the latest clinical reports on COVID-19 and cytokine storm syndrome, as well as the clinical role of NF-κβ in COVID-19 pathogenesis, including results from the literature on Montelukast and its ability to modulate NF-κβ, reduce cytokine production, and mitigate RNA virus infections. Currently, as part of a larger team approach, we are preparing to initiate a clinical trial protocol for the study of the efficacy of Montelukast in patients who are newly identified as COVID-19 positive, The COvid-19 Symptom MOntelukast Trial (COSMO), NCT04389411. Also, we would share some anecdotal evidence from patients who got benefit by adding Montelukast in their drug regimen. |
| Please indicate who nominated you | Rady Faculty of Health Science, University of Manitoba |
| What Canadian Institutes of Health Research (CIHR) institute is your research most closely aligned? | Infection and Immunity |
| What Canadian Institutes of Health Research (CIHR) pillar of health research does your research fall under? | Biomedical |
| PDF of abstract | Abstract Submission_ICAM_2023_Sanghai.pdf 2023-01-27 at 23:04:24 |
| Presenter and Author(s) | Nitesh Sanghai Nitesh Sanghai |
